LT5435B - Vakcinos kompozicijos mišinys su alkilfosfatidilcholinu - Google Patents

Vakcinos kompozicijos mišinys su alkilfosfatidilcholinu Download PDF

Info

Publication number
LT5435B
LT5435B LT2006036A LT2006036A LT5435B LT 5435 B LT5435 B LT 5435B LT 2006036 A LT2006036 A LT 2006036A LT 2006036 A LT2006036 A LT 2006036A LT 5435 B LT5435 B LT 5435B
Authority
LT
Lithuania
Prior art keywords
response
vaccine
antigen
ethyl
phosphatidylcholine
Prior art date
Application number
LT2006036A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2006036A (en
Inventor
Jean Haensler
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of LT2006036A publication Critical patent/LT2006036A/xx
Publication of LT5435B publication Critical patent/LT5435B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LT2006036A 2003-11-17 2006-05-17 Vakcinos kompozicijos mišinys su alkilfosfatidilcholinu LT5435B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313406A FR2862306B1 (fr) 2003-11-17 2003-11-17 Composition vaccinale

Publications (2)

Publication Number Publication Date
LT2006036A LT2006036A (en) 2007-05-25
LT5435B true LT5435B (lt) 2007-07-25

Family

ID=34508504

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2006036A LT5435B (lt) 2003-11-17 2006-05-17 Vakcinos kompozicijos mišinys su alkilfosfatidilcholinu

Country Status (23)

Country Link
US (2) US7344720B2 (pt)
EP (1) EP1696954B1 (pt)
JP (1) JP4638880B2 (pt)
KR (1) KR101136107B1 (pt)
CN (1) CN1882358B (pt)
AT (1) ATE412429T1 (pt)
AU (1) AU2004290943B2 (pt)
BR (1) BRPI0416670A (pt)
CA (1) CA2545086C (pt)
CY (1) CY1108498T1 (pt)
DE (1) DE602004017504D1 (pt)
DK (1) DK1696954T3 (pt)
ES (1) ES2311875T3 (pt)
FR (1) FR2862306B1 (pt)
IL (1) IL175573A (pt)
LT (1) LT5435B (pt)
LV (1) LV13457B (pt)
NO (1) NO20062779L (pt)
PL (1) PL1696954T3 (pt)
PT (1) PT1696954E (pt)
SI (1) SI1696954T1 (pt)
WO (1) WO2005049080A1 (pt)
ZA (1) ZA200603522B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
CA2761924C (fr) 2009-05-14 2017-10-31 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
AU2010247253A1 (en) * 2009-05-14 2012-01-12 Sanofi Pasteur Method for detoxification of lipopolysaccharide (LPS) or of lipid a of gram-negative bacteria
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
JP5761143B2 (ja) * 2011-11-02 2015-08-12 株式会社リコー 撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) * 2012-11-29 2014-05-29 Antonius Arnoldus Christiaan Jacobs Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
AU2014234452B2 (en) 2013-03-18 2018-02-22 Intervet International B.V. Vaccine to protect a ruminant against pneumonia caused by Mannheimia haemolytica
BR112016031039B1 (pt) 2014-07-21 2022-02-15 Sanofi Pasteur Sa Dispositivo de alimentação de líquido para a geração de gotículas, linha de processo para a produção de partículas liofilizadas e processos para preparar uma composição de vacina compreendendo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033346A1 (en) 1997-12-26 1999-07-08 Biovacs. Inc. Anti-retroviral immunogens, preparation and use
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260291T3 (es) 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
WO1999033346A1 (en) 1997-12-26 1999-07-08 Biovacs. Inc. Anti-retroviral immunogens, preparation and use

Also Published As

Publication number Publication date
ZA200603522B (en) 2007-07-25
ES2311875T3 (es) 2009-02-16
IL175573A0 (en) 2006-09-05
LT2006036A (en) 2007-05-25
SI1696954T1 (sl) 2009-04-30
CN1882358B (zh) 2011-02-02
FR2862306A1 (fr) 2005-05-20
WO2005049080A1 (fr) 2005-06-02
FR2862306B1 (fr) 2008-05-30
US7767658B2 (en) 2010-08-03
US7344720B2 (en) 2008-03-18
EP1696954B1 (fr) 2008-10-29
CY1108498T1 (el) 2014-04-09
US20050208060A1 (en) 2005-09-22
EP1696954A1 (fr) 2006-09-06
CN1882358A (zh) 2006-12-20
PT1696954E (pt) 2008-11-25
WO2005049080B1 (fr) 2005-09-01
ATE412429T1 (de) 2008-11-15
AU2004290943A1 (en) 2005-06-02
AU2004290943B2 (en) 2009-08-27
LV13457B (en) 2007-01-20
PL1696954T3 (pl) 2009-04-30
US20080131446A1 (en) 2008-06-05
KR101136107B1 (ko) 2012-04-17
CA2545086C (en) 2011-11-08
CA2545086A1 (en) 2005-06-02
DK1696954T3 (da) 2009-02-23
DE602004017504D1 (de) 2008-12-11
IL175573A (en) 2010-06-30
JP2007511585A (ja) 2007-05-10
JP4638880B2 (ja) 2011-02-23
NO20062779L (no) 2006-08-15
KR20060127385A (ko) 2006-12-12
BRPI0416670A (pt) 2007-02-13

Similar Documents

Publication Publication Date Title
US7767658B2 (en) Vaccine composition
JP3755890B2 (ja) アジュバント含有ワクチン組成物
US5919480A (en) Liposomal influenza vaccine composition and method
JP4535211B2 (ja) コクリエート送達ビヒクル
ES2140076T5 (es) Vacunas que contienen una saponina y un esterol.
AU689505B2 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US20070298093A1 (en) Synergistic Liposomal Adjuvants
ES2180703T5 (es) Composiciones de vacunas para mamiferos que comprenden escualeno o escualano, un fosfolipido y un tensioactivo como adyuvante.
JP2007514725A (ja) 少なくとも１つのトール様受容体７またはトール様受容体８アゴニストおよびトール様受容体４アゴニストを含む免疫賦活性組成物
MXPA06005486A (es) Composicion de vacuna mezclada con una alquilfosfatidilcolina

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20131115